Leishmania donovani ornithine decarboxylase is indispensable for parasite survival in the mammalian host

Infection and Immunity

Volumn 77, Issue 2, 2009, Pages 756-763

  Boitz, Jan M ^a   Yates, Phillip A ^a   Kline, Chelsey ^b   Gaur, Upasna ^c   Wilson, Mary E ^c   Ullman, Buddy ^a   Roberts, Sigrid C ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b PACIFIC UNIVERSITY   (United States)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFLORNITHINE; ORNITHINE DECARBOXYLASE; POLYAMINE DERIVATIVE; PUTRESCINE;

AMASTIGOTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DESTRUCTION; CONTROLLED STUDY; EPISOME; FEMALE; GENE; GENETIC COMPLEMENTATION; HOST CELL; HOST PARASITE INTERACTION; LEISHMANIA DONOVANI; MACROPHAGE; MAMMAL; MOUSE; MUTANT; NONHUMAN; ODC GENE; PARASITEMIA; PHENOTYPE; PRIORITY JOURNAL; PROMASTIGOTE; SURVIVAL; VISCERAL LEISHMANIASIS; WILD TYPE; ANIMAL; BAGG ALBINO MOUSE; CYTOLOGY; DRUG EFFECT; ENZYMOLOGY; GENE DELETION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PARASITOLOGY;

ANIMALS; FEMALE; GENE DELETION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HOST-PARASITE INTERACTIONS; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; MACROPHAGES; MICE; MICE, INBRED BALB C; ORNITHINE DECARBOXYLASE; PUTRESCINE;

EID: 60549113705     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.01236-08     Document Type: Article

References (59)

1. Assaraf, Y. G., J. Golenser, D. T. Spira, G. Messer, and U. Bachrach. 1987. Cytostatic effect of DL-alpha-difluoromethylornithine against Plasmodium falciparum and its reversal by diamines and spermidine. Parasitol. Res. 73:313-318.
2. Bacchi, C. J., and P. P. McCann. 1987. Parasitic protozoa and polyamines. p. 317-344. In P. P. McCann. A. E. Pegg. and A. Sjoerdsma (ed.), Inhibition of polyamine metabolism: biological significance and basis for new therapies. Academic Press. Orlando, FL.
3. Bacchi, C. J., H. C. Nathan, N. Yarlett, B. Goldberg, P. P. McCann, A. J. Bitonti, and A. Sjoerdsma. 1992. Cure of murine Trypanosoma brucei rhodesiense infections with an S- adenosylmethionine decarboxylase inhibitor. An-timicrob. Agents Chemother. 36:2736-2740.
4. Bacchi, C. J., and N. Yarlett. 1995. Polyamine metabolism. In J. J. Marr and M. Muller (ed.), Biochemistiy and molecular biology of parasites, p. 119- 131. Academic Press Ltd., London, United Kingdom.
5. Bachrach, U, 2005. Naturally occurring polyamines: interaction with macro-molecules. Curr. Protein Pept. Sci. 6:559-566.
6. Basselin, M-, G. H. Coombs, and M. P. Barrett. 2000. Putrescine and spermidine transport in Leishmania. Mol. Biochem. Parasitol. 109:37-46.
7. Beverley, S. M. 1991. Gene amplification in Leishmania. Annu. Rev. Microbiol. 45:417-44.
8. Bitonti, A. J., T. L. Byers, T. L. Bush, P. J. Casara, C. J. Bacchi, A. B. Clarkson, Jr., P. P. McCann, and A. Sjoerdsma. 1990. Cure of Trypanosoma brucei brucei and Trypanosoma brucei rhodesiense infections in mice with an irreversible inhibitor of S-adenosylmethionine decarboxylase. Antimicrob. Agents Chemother. 34:1485-1490.
9. Bitonti, A. J., J. A, Dumont, and P. P. McCann. 1986. Characterization of Trypanosoma brucei brucei S-adenosyl-L-methionine decarboxylase and its inhibition by Berenil, pentamidine and methylglyoxal bis(guanylhydrazone). Biochem. J. 237:685-689.
10. Bitonti, A. J., P. P. McCann, and A. Sjoerdsma. 1987. Plasmodium falciparum and Plasmodium berghei: effects of ornithine decarboxylase inhibitors on erythrocytic schizogony. Exp. Parasitol. 64:237-243.
11. Blackwell, J. M. 1996. Genetic susceptibility to leishmanial infections: studies in mice and man. Parasitology 112 (Suppl.):S67-S74.
12. Boucher, N., F. McNicoll, M. Laverdiere, A. Rochette, M. N. Chou, and B. Papadopoulou. 2004. The ribosomal RNA gene promoter and adjacent cis-acting DNA sequences govern plasmid DNA partitioning and stable inheritance in the parasitic protozoan Leishmania. Nucleic Acids Res. 32:2925-2936.
13. Buffet, P. A., A. Sulahian, Y. J. Garin, N. Nassar, and F. Derouin. 1995. Culture microtitration: a sensitive method for quantifying Leishmania infantum in tissues of infected mice. Antimicrob. Agents Chemother. 39:2167-2168.
14. Burri, C., and R. Brun. 2003. Eflornithine for the treatment of human African trypanosomiasis. Parasitol. Res. 90(Supp. 1):S49-S52.
15. Chang, K. P., R. F. Steiger, C. Dave, and Y. C. Cheng. 1978. Effects of methylglyoxal bis(ganylhydrazone) on trypanosomatid flagellates: inhibition of growth and nucleoside incorporation in Trypanosoma brucei. J. Protozool. 25:145-149.
16. Clayton, C. E. 1999. Genetic manipulation of kinetoplastida. Parasitol. Today 15:372-378.
17. Cohen, S. S. 1998. A guide to the polyamines. Oxford University Press, Oxford, United Kingdom.
18. Danzin, C., P. Marchal, and P. Casara. 1990. Irreversible inhibition of rat S-adenosylmethionine decarboxylase by 5′-([(Z)-4-amino- 2-butenyl]methyl-amino)-5′-deoxyadenosine. Biochem. Pharmacol. 40:1499-1503.
19. Debrabant, A., M. B. Joshi, P. F. Pimenta, and D. M. Dwyer. 2004. Generation of Leishmania donovani axenic amastigotes: their growth and biological characteristics. Int. J. Parasitol. 34:205-217.
20. Docampo, R., and S. N. Moreno. 2003. Current chemotherapy of human African trypanosomiasis. Parasitol. Res. 90(Supp. 1):S10-S13.
21. Garg, R., and A. Dube. 2006. Animal models for vaccine studies for visceral leishmaniasis. Indian J. Med. Res. 123:439-454.
22. Gaur, U., S. C. Roberts, R. P. Dalvi, I. Corraliza, B. Ullman, and M. E. Wilson. 2007. An effect of parasite-encoded arginase on the outcome of murine cutaneous leishmaniasis. J. Immunol. 179:8446-8453.
23. Geary, T. G., S. A. Edgar, and J. D. Jensen. 1986. Drug resistance in protozoa, p. 209-236. In W. C. Campbell and R. S. Rew (ed.). Chemotherapy of parasitic diseases. Plenum Press, New York. NY.
24. Gillin, F. D., D. S. Reiner, and P. P. McCann. 1984. Inhibition of growth of Giardia lamblia by difluoromethylornithine, a specific inhibitor of polyamine biosynthesis. J. Protozool. 31:161-163.
25. Goyard, S., and S. M. Beverley. 2000. Blasticidin resistance: a new independent marker for stable transfection of Leishmania. Mol. Biochem. Parasitol. 108:249-252.
26. Goyard, S., H. Segawa, J. Gordon, M. Showalter, R. Duncan, S. J. Turco, and S. M. Beverley. 2003. An in vitro system for developmental and genetic studies of Leishmania donovani phosphoglycans. Mol. Biochem. Parasitol. 130:31-2.
27. Gradoni, L., M. A. Iorio, M. Gramiccia, and S. Orsini. 1989. In vivo effect of eflornithine (DFMO) and some related compounds on Leishmania infantum preliminary communication. Farmaco 44:1157-1166.
28. Hanson, S., J. Adelman, and B. Ullman. 1992. Amplification and molecular cloning of the ornithine decarboxylase gene of Leishmania donovani. J. Biol. Chem. 267:2350-2359.
29. Janne, J., L. Alhonen, T. A. Keinanen, M. Pietila, A. Uimari, E. Pirinen, M. T. Hyvonen, and A. Jarvinen. 2005. Animal disease models generated by genetic engineering of polyamine metabolism. J. Cell Mol. Med. 9:865-882.
30. Janne, J., L. Alhonen, M. Pietila, and T. A. Keinanen. 2004. Genetic approaches to the cellular functions of polyamines in mammals. Eur. J. Biochem. 271:877-894.
31. Jiang, Y., S. C. Roberts, A. Jardim, N. S. Carter, S. Shih, M. Ariyanayagam, A. H. Fairlamb, and B. Ullman. 1999. Ornithine decarboxylase gene deletion mutants of Leishmania donovani. J. Biol. Chem. 274:3781-3788.
32. Kaur, K., K. Emmett, P. P. McCann, A. Sjoerdsma, and B. Ullman. 1986. Effects of DL-alpha-difluoromethylomithine on Leishmania donovani promastigotes. J. Protozool. 33:518-521.
33. Kaye, P. M., P. Gorak, M. Murphy, and S. Ross. 1995. Strategies for immune intervention in visceral leishmaniasis. Ann. Trop. Med. Parasitol. 89(Suppl. i):75-81.
34. Keithly, J. S., and A. H. Fairlamb. 1987. Inhibition of Leishmania species by alpha-difluoromethyloraithine, p. 749-756. In D. T. Hart (ed.), Leishmaniasis: the current status and new strategies for control, vol. 163. Plenum Press. New York, NY.
35. Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685.
36. McCann, P., C. J. Bacchi, W. L, Hanson, G. D. Cain, H. C. Nathan, S. H. Hutner, and A. Sjoerdsma. 1981. Effect on parasitic protozoa of alpha-difluoromethylornithine, an inhibitor of ornithine decarboxylase. Adv. Polyamine Res. 3:97-110.
37. Metcalf, B. W., P. Bey, C. Danzin, M. J. Jung, P. Casara, and J. P. Vevert. 1978. Catalytic irreversible inhibition of mammalian ornithine decarboxylase (E.C. 4.1.1.17) by substrate and product analogues. J. Am. Chem. Soc. 100:2551-2553.
38. Mishra, J., A. Saxena, and S. Singh. 2007. Chemotherapy of leishmaniasis: past, present and future. Curr. Med. Chem. 14:1153-1169.
39. Mukhopadhyay, R., P. Kapoor, and R. Madhubala. 1996. Characterization of alpha-difluoromethylornithine resistant Leishmania donovani and its susceptibility to other inhibitors of the polyamine biosynthetic pathway. Pharmacol. Res. 34:43-46.
40. Mukhopadhyay, R., and R. Madhubala. 1993. Effect of a bis(benzyl)poly-amine analogue, and DL-alpha-difluoromethylornithine on parasite suppression and cellular polyamine levels in golden hamster during Leishmania donovani infection. Pharmacol. Res. 28:359-365.
41. Mullen, A. B., A. J. Baillie, and K. C. Carter. 1998. Visceral leishmaniasis in the BALB/c mouse: a comparison of the efficacy of a nonionic surfactant formulation of sodium stibogluconate with those of three proprietary formulations of amphotericin B. Antimicrob. Agents Chemother. 42:2722-2725.
42. Na-Bangchang, K., F. Doua, J. Konsil, W. Hanpitakpong, B. Kamanikom, and F. Kuzoe. 2004. The pharmacokinetics of eflornithine (alpha-difluoro-methylornithine) in patients with late-stage T.b. gambiense sleeping sickness. Eur. J. Clin. Pharmacol. 60:269-278.
43. Osterman, A., N. V. Grishin, L. N. Kinch, and M. A. Phillips. 1994. Formation of functional cross-species heterodimers of ornithine decarboxylase. Biochemistry 33:13662-13667.
44. Pepin, J., and F. Milord. 1994. The treatment of human African trypanosomiasis. Adv. Parasitol. 33:1-47.
45. Reguera, R. M., R. B. Fouce, J. C. Cubria, M. L. Bujidos, and D. Ordonez. 1995. Fluorinated analogues of L-ornithine are powerful inhibitors of ornithine decarboxylase and cell growth of Leishmania infantum promastigotes. Life Sci. 56:223-230.
46. Roberts, S. C., Y. Jiang, J. Gasteier, B. Frydman, L. J. Marton, O. Heby, and B. Ullman. 2007. Leishmania donovani polyamine biosynthetic enzyme over-producers as tools to investigate the mode of action of cytotoxic polyamine analogs. Antimicrob. Agents Chemother. 51:438-445.
47. Roberts, S. C., Y. Jiang, A. Jardim, N. S. Carter, O. Heby, and B. Ullman. 2001. Genetic analysis of spermidine synthase from Leishmania donovani. Mol. Biochem. Parasitol. 115:217-226.
48. Roberts, S. C., J. Scott, J. E. Gasteier, Y. Jiang, B. Brooks, A. Jardim, N. S. Carter, O. Heby, and B. Ullman. 2002. S-adenosylmethionine decarboxylase from Leishmania donovani. Molecular, genetiC., and biochemical characterization of null mutants and overproducers. J. Biol. Chem. 277:5902-5909.
49. Roberts, S. C., M. J. Tancer, M. R. Polinsky, K. M. Gibson, O. Heby, and B. Ullman. 2004. Arginase plays a pivotal role in polyamine precursor metabolism in Leishmania. Characterization of gene deletion mutants. J. Biol. Chem. 279:23668-23678.
50. Sanchez, C. P., J. Mucci, N. S. Gonzalez, A. Ochoa, M. M. Zakin, and I. D. Algranati. 1997. Alpha-difluoromethylornithine-resistant cell lines obtained after one-step selection of Leishmania mexicana promastigote cultures. Biochem. J. 324:847-853.
51. Schechter, P. J., J. L. R. Barlow, and A. Sjoerdsma. 1987. Clinical aspects of inhibition of ornithine decarboxylase with emphasis on therapeutic trials of eflornithine (DFMO) in cancer and protozoan diseases, p. 345-364. In P. P. McCann, A. E. Pegg, and A. Sjoerdsma (ed.), Inhibition of polyamine metabolism: biological significance and basis for new therapies. Academic Press, Orlando. EL.
52. Tabor, C. W., and H. Tabor. 1984. Polyamines. Annu. Rev. Biochem. 53: 749-790.
53. Towbin, H., T. Staehelin, and J. Gordon. 1979. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. USA 76:4350-4354.
54. Ulrich, P., R. W. Grady, and A. Cerami. 1982. The trypanocidal activity of various aromatic bisguanylhydrazones in vivo. Drug Dev. Res. 2:219-228.
55. Van Nieuwenhove, S., P. J. Schechter, J. Declercq, G. Bone, J. Burke, and A. Sjoerdsma. 1985. Treatment of gambiense sleeping sickness in the Sudan with oral DFMO (DL-alpha-difluoromethylomithine), an inhibitor of ornithine decarboxylase; first field trial. Trans. R. Soc. Trop. Med. Hyg. 79:692-698.
56. Vergnes, B., D. Sereno, J. Tavares, A. Cordeiro-da-Silva, L. Vanhille, N. Madjidian-Sereno, D. Depoix, A. Monte-Alegre, and A. Ouaissi. 2005. Targeted disruption of cytosolic SIR2 deacetylase discloses its essential role in Leishmania survival and proliferation. Gene 363:85-96.
57. Wang, C. C. 1995. Molecular mechanisms and therapeutic approaches to the treatment of African trypanosomiasis. Annu. Rev. Pharmacol. Toxicol. 35: 93-127.
58. Wilson, M. E., S. M. Jeronimo, and R. D. Pearson. 2005. lmmunopathogen-esis of infection with the visceralizing Leishmania species. Microb. Pathog. 38:147-160.
59. Zhang, W. W., H. Charest, E. Ghedin, and G. Matlashewski. 1996. Identification and overexpression of the A2 amastigote-specific protein in Leishmania donovani. Mol. Biochem. Parasitol. 78:79-90.